Enteric Disease Testing Market Size is likely to witness a significant upsurge from 2022 to 2028, considering the global burden of mortality and morbidity such as cognitive impairment among patients infected with enteric pathogens, including norovirus. The strong focus on the development of cost-effective treatments to reduce enteric disease infections in lower- and low-middle-income countries will further escalate industry share in the upcoming years. Enteric diseases refer to intestinal illnesses caused by parasites, bacteria, viruses, and other micro-organisms. This type of disease mainly occurs due to the consumption of contaminated water or food, and it can also spread from person to person. Gastrointestinal pathogen panels are generally used to test the presence of disease causing-viruses, parasites, and bacteria in stool samples, as well as help diagnose digestive system infection.
Mounting sales of frozen foods and ready-to-eat meals are some of the key trends characterizing the enteric disease testing market dynamics through 2022-2028. The American Frozen Food Institute, for example, introduced the Enteric Viruses Control Program to make recommendations for frozen fruit processors, re-packers, and berry growers to control enteric viruses including Hepatitis A. Such factors, along with the rising implementation of standards for food business operators to ensure cleanliness among cattle and sheep, will further augment the need for the testing of enteric disease in poultry and meat products.
Based on testing method, the molecular diagnostic testing segment will hold an appreciable share in the enteric disease testing market by 2028. This can be credited to the rapid development of high throughput, real-time PCR systems for the detection of viral and bacterial enteric diseases. Likewise, the robust demand for genomic and genetic information has led to the expansion of molecular diagnostic options in the healthcare spectrum, thus providing growth opportunities for this testing method in the years ahead.
North America enteric disease testing market is projected to amass considerable gains by 2028, as a result of the growing prevalence of typhoid fever in the U.S., mostly acquired owing to international travel. Nearly 500 people in the country are infected with the typhoid Salmonella virus annually. This factor, coupled with the high emphasis on the investigation, tracking, and prevention of foodborne infections in the country, will stimulate the requirement of enteric infection treatment and testing in the region.
Some of the major players functioning in the enteric disease testing industry include Trinity Biotech, Quest Diagnostics, Meridian Bioscience, DiaSorin, Coris Bioconcept SPRL, Cepheid Inc. (Danaher Corporation), Bio-Rad Laboratories, Biomerieux SA (Institut Mérieux, Sofina), Alere and Biomerica, among others. These companies are focusing on mergers, acquisitions, and new service launches to strengthen their presence across the competitive market.
The novel coronavirus pandemic posed a dramatic impact on the diagnosis of infectious diseases as well as clinical laboratory operations because of the shortage of reagents and supplies, among other challenges during its peak. Several laboratories also shifted their focus towards SARS-CoV-2 testing in the initial months, hence affecting other infectious disease testing procedures, including enteric disease testing Despite these COVID-19-induced disruptions, the exponential rise in the sales of frozen goods during the pandemic may aid industry recovery in the near future. As per the Food Industry Association and American Frozen Food’s report, the frozen food segment was a fast-growing category in grocery stores during COVID-19, which could drive the need for testing of viruses like Hepatitis A in such food products over the foreseeable future.
Market, by Disease Indication
Market, by Testing Methods
Market, by End-users
The above information is provided for the following regions and countries: